JP2025508066A5 - - Google Patents

Info

Publication number
JP2025508066A5
JP2025508066A5 JP2024553409A JP2024553409A JP2025508066A5 JP 2025508066 A5 JP2025508066 A5 JP 2025508066A5 JP 2024553409 A JP2024553409 A JP 2024553409A JP 2024553409 A JP2024553409 A JP 2024553409A JP 2025508066 A5 JP2025508066 A5 JP 2025508066A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
light chain
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024553409A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508066A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2023/000124 external-priority patent/WO2023170474A1/en
Publication of JP2025508066A publication Critical patent/JP2025508066A/ja
Publication of JP2025508066A5 publication Critical patent/JP2025508066A5/ja
Pending legal-status Critical Current

Links

JP2024553409A 2022-03-07 2023-03-07 目的としたt細胞活性化のためのcd28二重特異性抗体 Pending JP2025508066A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263317491P 2022-03-07 2022-03-07
US63/317,491 2022-03-07
US202263323893P 2022-03-25 2022-03-25
US63/323,893 2022-03-25
PCT/IB2023/000124 WO2023170474A1 (en) 2022-03-07 2023-03-07 Cd28 bispecific antibodies for targeted t cell activation

Publications (2)

Publication Number Publication Date
JP2025508066A JP2025508066A (ja) 2025-03-21
JP2025508066A5 true JP2025508066A5 (https=) 2026-03-17

Family

ID=86272440

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024553409A Pending JP2025508066A (ja) 2022-03-07 2023-03-07 目的としたt細胞活性化のためのcd28二重特異性抗体

Country Status (8)

Country Link
US (1) US20240002544A1 (https=)
EP (1) EP4490192A1 (https=)
JP (1) JP2025508066A (https=)
CN (1) CN119233993A (https=)
AU (1) AU2023232992A1 (https=)
CA (1) CA3249273A1 (https=)
IL (1) IL314916A (https=)
WO (1) WO2023170474A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL305828A (en) * 2021-03-22 2023-11-01 Novimmune Sa Bispecific antibodies targeting CD47 and PD-L1 and methods of using them
EP4493592A1 (en) 2022-03-14 2025-01-22 LamKap Bio gamma AG Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells
US20240254234A1 (en) 2022-10-21 2024-08-01 Novimmune Sa PD-L1xCD28 BISPECIFIC ANTIBODIES FOR IMMUNE CHECKPOINT-DEPENDENT T CELL ACTIVATION
WO2025051895A1 (en) * 2023-09-06 2025-03-13 Novimmune Sa Combination therapy with a cea x cd28 bispecific antibody and blocking anti-pd-1 antibodies for enhanced in vivo anti-tumor activity
TW202544034A (zh) * 2024-05-06 2025-11-16 美商榮都醫療公司 結合至cd28及nectin-4之雙特異性抗體
WO2026078067A1 (en) 2024-10-08 2026-04-16 Novimmune Sa Fcrh5 monospecific antibodies and derived fcrh5xcd28 bispecific antibodies and use thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
PT2171060E (pt) 2004-11-11 2013-11-18 Theramab Llc Anticorpo anti-cd28 superagonista
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー/エス 二重特異性抗体の生産
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
HRP20241208T1 (hr) 2010-04-20 2024-11-22 Genmab A/S Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju
CN103261220B (zh) 2010-08-16 2016-06-15 诺夫免疫股份有限公司 用于生成多特异性和多价抗体的方法
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
PE20141017A1 (es) 2011-03-02 2014-08-25 Roche Glycart Ag Anticuerpos del cea
BR112014010580B1 (pt) 2011-11-04 2021-01-12 Zymeworks, Inc. constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado
LT2961771T (lt) 2013-02-26 2020-03-10 Roche Glycart Ag Bispecifinės t ląstelę aktyvinančios antigeną surišančios molekulės, specifinės cd3 ir cea antigenams
WO2016036678A1 (en) 2014-09-02 2016-03-10 Medimmune, Llc Formulations of bispecific antibodies
WO2018209304A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
US11260117B2 (en) * 2017-05-26 2022-03-01 Novimmune Sa Anti-CD47 x anti-mesothelin antibodies and methods of use thereof
AU2018303254B2 (en) * 2017-07-21 2025-05-29 Novimmune Sa Generating multispecific antibody mixtures and methods of uses thereof
EP3802599B1 (en) * 2018-06-03 2023-12-20 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
IL279354B1 (en) 2018-06-21 2026-02-01 Regeneron Pharma Bispecific antibodies against psma and against cd28 and their uses
US11453721B2 (en) 2018-12-19 2022-09-27 Regeneran Pharmaceuticals, Inc. Bispecific anti-MUC16 x anti-CD28 antibodies and uses thereof
MA54540A (fr) 2018-12-19 2021-10-27 Regeneron Pharma Anticorps anti-cd28 x anti-cd22 bispécifiques et leurs utilisations
WO2020127628A1 (en) 2018-12-21 2020-06-25 F. Hoffmann-La Roche Ag Tumor-targeted superagonistic cd28 antigen binding molecules
UA128001C2 (uk) 2018-12-21 2024-03-06 Ф. Хоффманн-Ля Рош Аг Націлені на пухлину агоністичні cd28-антигензв'язувальні молекули
CA3134335A1 (en) 2019-03-22 2020-10-01 Regeneron Pharmaceuticals, Inc. Egfr x cd28 multispecific antibodies
WO2021053587A1 (en) 2019-09-18 2021-03-25 Klaus Strein Bispecific antibodies against ceacam5 and cd3
EP3831849A1 (en) 2019-12-02 2021-06-09 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
JP7789002B2 (ja) 2020-01-29 2025-12-19 インヒブルクス バイオサイエンシズ インコーポレイテッド Cd28シングルドメイン抗体ならびにその多価および多重特異性の構築物
AU2021295549A1 (en) 2020-06-23 2022-11-24 F. Hoffmann-La Roche Ag Agonistic CD28 antigen binding molecules targeting Her2
CA3192204A1 (en) 2020-08-19 2022-02-24 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
HRP20240213T1 (hr) * 2020-12-18 2024-04-26 Lamkap Bio Beta Ag Bispecifična antitijela protiv ceacam5 i cd47

Similar Documents

Publication Publication Date Title
JP2025508066A5 (https=)
JP2024504384A5 (https=)
JP2025160458A5 (https=)
JP2021534096A5 (https=)
JP2021533159A5 (https=)
JP2022075818A5 (https=)
JP2020079252A5 (https=)
JP2023509448A5 (https=)
JP2023123726A5 (https=)
JP2024542194A5 (https=)
RU2017134495A (ru) Антитела к альфа-рецептору собачьего интерлейкина-4
JP2022525377A5 (https=)
RU2009129403A (ru) Антитела, нейтрализующие цитомегаловирус человека, и их применение
JP2022533538A5 (https=)
JP2021520832A5 (https=)
JP2023549537A5 (https=)
JP2023540526A5 (https=)
JP2024532489A5 (https=)
JP2023548529A5 (https=)
JP2025501775A5 (https=)
JP2024540148A5 (https=)
JP2024001073A5 (https=)
JP2023510982A5 (https=)
JP2021511387A5 (https=)
JP2024512574A5 (https=)